Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709542 | 0.88 | MAOA (0.62) | MAOAMAOBTNFCYP19A1HTT | |
| SCHEMBL24062 | 0.80 | MEN1 (0.37) | MAOAMAOBHTTCDC25BSMN1; SMN2 | |
| SCHEMBL27971780 | 0.77 | MEN1 (0.35) | MAOAMAOBHTTCDC25BSMN1; SMN2 | |
| SCHEMBL27860206 | 0.77 | MEN1 (0.35) | MAOAMAOBHTTCDC25BSMN1; SMN2 | |
| SCHEMBL9709023 | 0.75 | MAOA (0.62) | MAOAMAOBTNFCYP19A1HTT | |
| SCHEMBL28512593 | 0.72 | MAOA (0.65) | MAOAMAOBTNFCYP19A1CYP11B2 | |
| SCHEMBL19764657 | 0.72 | MAOA (0.65) | MAOAMAOBTNFCYP19A1CYP11B2 | |
| SCHEMBL14380259 | 0.72 | MAOA (0.65) | MAOAMAOBTNFCYP19A1CYP11B2 | |
| SCHEMBL27971618 | 0.70 | CYP1A2 (0.31) | CDC25BIDO1CYP1A2CYP2D6 | |
| SCHEMBL1750489 | 0.65 | MEN1 (0.58) | MAOAMAOBHTTCDC25BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49118-E1 | Material for organic electroluminescence device and electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2022-06-28 | — | — | US | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| EP-1183252-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | claimed |
| US-6492406-B1 | PROTEIN KINASE C INHIBITORS; ANTIINFLAMMATORY AND IMMUNO-SUPPRESSIVE AGENTS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | claimed |
| EP-0654495-B1 | Photoconductive film formed from a grafted silane polymer; process for preparing and process for the formation of an electrostatic image of this film and an optical valve based on this film | FRANCE TELECOM (FR) | 1999-01-27 | — | — | EP | claimed |
| EP-0548553-A1 | Optically active azole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-06-30 | — | — | EP | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3630772-B1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | IMARA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| US-RE49118-E1 | Material for organic electroluminescence device and electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Imara Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220185836-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS | XLINK THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-5069991-A | NAPHTHOLACTAM OR ISINDOLENINE DYE | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0364890-A2 | Panchromatic electrophotographical recording element | BASF Aktiengesellschaft (DE) | 1990-04-25 | — | — | EP | disclosed |
| US-4906541-A | Electrophotographic recording element containing a naphtholactam dye sensitizer | BASF AKTIENGESELLSCHAFT (DE) | 1990-03-06 | — | — | US | disclosed |
| US-4451462-A | Method of treating inflammation and pain using heteramino benzofurans | CIBA-GEIGY CORPORATION (US) | 1984-05-29 | — | — | US | disclosed |
| US-4426380-A | ANTIINFLAMMATORY, ANALGESIC, SUNSCREEN | CIBA-GEIGY CORPORATION (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0082109-A2 | Substituted 2-hydroxyphenylacetic acids and derivatives of them | CIBA-GEIGY AG (CH) | 1983-06-22 | — | — | EP | disclosed |
| EP-0078241-A2 | Furanes | CIBA-GEIGY AG (CH) | 1983-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185836-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS | TP53, VHL, KRAS | MAOA 4293/4885MAOB 3510/4885TNF 4546/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | MAOA 893/4885MAOB 1546/4885TNF 4181/4885 |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | XBP1, HSPA5, ATF4 | MAOA 4665/4885MAOB 4775/4885TNF 4090/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | MAOA 1197/4885MAOB 828/4885TNF 1580/4885 |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | TYMS, TKT, TPMT | MAOA 1439/4885MAOB 2349/4885TNF 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.